DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Purinethol (Mercaptopurine) - Summary



PURINETHOL (mercaptopurine) was synthesized and developed by Hitchings, Elion, and associates at the Wellcome Research Laboratories. It is one of a large series of purine analogues which interfere with nucleic acid biosynthesis and has been found active against human leukemias.

PURINETHOL (mercaptopurine) is indicated for remission induction and maintenance therapy of acute lymphatic leukemia. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric patient or adult).

Acute Lymphatic (Lymphocytic, Lymphoblastic) Leukemia: Given as a single agent for remission induction, PURINETHOL induces complete remission in approximately 25% of pediatric patients and 10% of adults. However, reliance upon PURINETHOL alone is not justified for initial remission induction of acute lymphatic leukemia since combination chemotherapy with vincristine, prednisone, and L-asparaginase results in more frequent complete remission induction than with PURINETHOL alone or in combination. The duration of complete remission induced in acute lymphatic leukemia is so brief without the use of maintenance therapy that some form of drug therapy is considered essential. PURINETHOL, as a single agent, is capable of significantly prolonging complete remission duration; however, combination therapy has produced remission duration longer than that achieved with PURINETHOL alone.

Acute Myelogenous (and Acute Myelomonocytic) Leukemia:    As a single agent, PURINETHOL will induce complete remission in approximately 10% of pediatric patients and adults with acute myelogenous leukemia or its subclassifications. These results are inferior to those achieved with combination chemotherapy employing optimum treatment schedules.

Central Nervous System Leukemia:    PURINETHOL is not effective for prophylaxis or treatment of central nervous system leukemia.

Other Neoplasms:    PURINETHOL is not effective in chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors.

See all Purinethol indications & dosage >>


Published Studies Related to Purinethol (Mercaptopurine)

Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia. [2010.08]
CONCLUSIONS: There were no differences in the EFS between the different maintenance therapies in each risk group; however, grade IV liver toxicity occurred more often in the patients receiving 6-MP/MTX with VCR and DEX therapy than in patients receiving LSA2L2. (c) 2010 Wiley-Liss, Inc.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. [2010.06.16]
CONCLUSIONS: Azathioprine and 6-mercaptopurine are effective therapy for inducing remission in active Crohn's disease. Adverse events were more common among patients on active therapy.

Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. [2010.04.10]
PURPOSE To describe event-free survival (EFS) and toxicities in children with low-risk acute lymphoblastic leukemia (ALL) assigned to receive either continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX) or intermittent 6-MP with intermediate-dose MTX, as maintenance treatment... Boys treated with the intermittent schedule had significantly better EFS.

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. [2010.04.08]
The Children's Cancer Group 1952 (CCG-1952) clinical trial studied the substitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (ITT) for intrathecal methotrexate (IT-MTX) in the treatment of standard-risk acute lymphoblastic leukemia...

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. [2010]
CONCLUSIONS: Azathioprine and 6-mercaptopurine are effective therapy for

more studies >>

Clinical Trials Related to Purinethol (Mercaptopurine)

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease [Recruiting]
The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP (mercaptopurine) drug (80 mg), as compared to standard Purinethol (at a dose of 1-1. 5 mg/kg/body weight), in alleviating the clinical, immunological and mucosal signs and symptoms of moderately active Crohn's Disease

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions [Recruiting]
The primary objective of this study is to determine whether the test product, mercaptopurine oral 100 mg/5 mL suspension, and the reference product, Purinethol® 50 mg tablets are bioequivalent. For this purpose the PK profile of 6-mercaptopurine (6-MP) will be compared after administration of a single dose of each of the two formulations, under fasting conditions. The secondary objective is to assess the safety and tolerability of the test product, mercaptopurine oral 100 mg/5 mL suspension.

Open Label Extension Study to Protocol C2/13/DR-6MP-02 [Not yet recruiting]
The open label extension study (Protocol C2/13/DR-6MP-02 EXT) is designed to evaluate the clinical efficacy and safety of 80 mg DR-6MP test formulation for an additional 12 weeks in subjects who already completed 12 weeks of Protocol C2/13/DR-6MP-02. Crohn's disease (CD) therapy is aimed at reducing inflammation via induction of remission after a flare-up and maintenance of the remission for as long as possible. The questions being asked in this extension study are:

1. For subjects who received 80 mg DR-6MP for 12 weeks: Can the clinical efficacy and safety status achieved following 12 weeks of treatment be maintained or improved following an additional 12 weeks of DR-6MP treatment?

2. For subjects who received oral Purinethol (1-1. 5 mg/kg daily) for 12 weeks: Can the clinical efficacy and safety at 12 weeks be maintained or improved following the introduction of 12 weeks of 80 mg DR-6MP treatment?

Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's mercaptopurine 50 mg tablets to Gate's Purinethol® 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.

A Clinical Trial in Patients With BRCA Defective Tumours [Recruiting]
This study will evaluate the efficacy and safety of 6MP in combination with methotrexate in patients with breast or ovarian cancer who are known to have a BRCA mutation. 6MP is used instead of 6TG as it is converted to the same cytotoxic moiety as 6TG, ie. thioguanine nucleotides, but with reduced toxic effects. Low dose methotrexate is used in combination with 6MP as it promotes the formation of thioguanine nucleotides.

more trials >>

Reports of Suspected Purinethol (Mercaptopurine) Side Effects

Diarrhoea (8)Crohn's Disease (7)Drug Ineffective (6)Abdominal Pain (5)Rectal Haemorrhage (5)Post Procedural Infection (5)Hyperbilirubinaemia (4)Hepatosplenic T-Cell Lymphoma (4)Weight Decreased (3)Cholestasis (3)more >>

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015